Advancing HFpEF Treatment with Novel MRAs - Episode 5
Evolving Guideline-Directed Medical Therapy Standards in HFpEF
Experts examine how updated guidelines are influencing the integration of novel MRAs and other agents into HFpEF treatment algorithms.
Panelists discussed how updated guidelines are reshaping the heart failure with preserved ejection fraction (HFpEF) treatment landscape. They noted that therapies once limited to HFpEF—such as sodium-glucose transporter 2 inhibitors and mineralocorticoid receptor antagonists—are now recommended for HFpEF based on emerging evidence.
The conversation explored how these shifts are improving consistency in care while highlighting gaps in implementation. Panelists stressed the importance of clinician education, standardized pathways, and equitable access to newer agents such as finerenone.
Experts agreed that guideline-directed therapy should balance efficacy with patient comorbidities and tolerability as evidence continues to evolve. Consistent adoption of these updates can narrow outcome disparities across the HFpEF population.
